Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 5/2012

01-10-2012 | Review

Aberrant microRNA expression and its implications in the pathogenesis of leukemias

Authors: Sadegh Babashah, Majid Sadeghizadeh, Mostafa Rezaei Tavirani, Shirin Farivar, Masoud Soleimani

Published in: Cellular Oncology | Issue 5/2012

Login to get access

Abstract

Background

MicroRNAs (miRNAs) are a class of non-coding, endogenous, small RNAs that negatively regulate gene expression by inducing degradation or translational inhibition of target mRNAs. Aberrant expression of miRNAs appears to be a common characteristic of hematological malignancies including leukemias.

Aim

Here we review the available data supporting a role of aberrant expression of miRNAs in the pathogenesis of leukemias including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL).

Conclusions

The expression signatures of miRNAs provide exciting opportunities in the diagnosis, prognosis, and therapy of leukemia. Since miRNAs can function as either oncogenes or tumor suppressor genes in leukemogenesis, the potential of using these small RNAs as therapeutic targets opens up new opportunities for leukemia therapy by either inhibiting or augmenting their activity.
Literature
1.
X. Liu, K. Fortin, Z. Mourelatos, MicroRNAs: biogenesis and molecular functions. Brain Pathol 18, 113–121 (2008)PubMedCrossRef
2.
S. Babashah, M. Soleimani, The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur. J. Cancer 47, 1127–1137 (2011)PubMedCrossRef
3.
R.C. Lee, R.L. Feinbaum, V. Ambros, The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843–854 (1993)PubMedCrossRef
4.
B.J. Reinhart, F.J. Slack, M. Basson, A.E. Pasquinelli, J.C. Bettinger, A.E. Rougvie, H.R. Horvitz, G. Ruvkun, The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403, 901–906 (2000)PubMedCrossRef
5.
M.J. Bueno, I. Perez de Castro, M. Malumbres, Control of cell proliferation pathways by microRNAs. Cell Cycle 7, 3143–3148 (2008)PubMedCrossRef
6.
Y. Lee, M. Kim, J. Han, K.H. Yeom, S. Lee, S.H. Baek, V.N. Kim, MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23, 4051–4060 (2004)PubMedCrossRef
7.
G.M. Borchert, W. Lanier, B.L. Davidson, RNA polymerase III transcribes human microRNAs. Nat. Struct. Mol. Biol. 13, 1097–1101 (2006)PubMedCrossRef
8.
Y. Lee, K. Jeon, J.T. Lee, S. Kim, V.N. Kim, MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 21, 4663–4670 (2002)PubMedCrossRef
9.
G. Hutvagner, P.D. Zamore, A microRNA in a multiple-turnover RNAi enzyme complex. Science 297, 2056–2060 (2002)PubMedCrossRef
10.
11.
M. Garofalo, C.M. Croce, microRNAs: Master regulators as potential therapeutics in cancer. Annu. Rev. Pharmacol. Toxicol. 51, 25–43 (2011)PubMedCrossRef
12.
O.A. Kent, J.T. Mendell, A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 25, 6188–6196 (2006)PubMedCrossRef
13.
14.
A. Esquela-Kerscher, F.J. Slack, Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 6, 259–269 (2006)PubMedCrossRef
15.
16.
M. Fabbri, R. Garzon, M. Andreeff, H.M. Kantarjian, G. Garcia-Manero, G.A. Calin, MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia 22, 1095–1105 (2008)PubMedCrossRef
17.
S. Yendamuri, G.A. Calin, The role of microRNA in human leukemia: a review. Leukemia 23, 1257–1263 (2009)PubMedCrossRef
18.
J. Kluiver, B.J. Kroesen, S. Poppema, A. van den Berg, The role of microRNAs in normal hematopoiesis and hematopoietic malignancies. Leukemia 20, 1931–1936 (2006)PubMedCrossRef
19.
R. Garzon, C.M. Croce, MicroRNAs in normal and malignant hematopoiesis. Curr. Opin. Hematol. 15, 352–358 (2008)PubMedCrossRef
20.
Z. Li, J. Lu, M. Sun, S. Mi, H. Zhang, R.T. Luo, P. Chen, Y. Wang, M. Yan, Z. Qian, M.B. Neilly, J. Jin, Y. Zhang, S.K. Bohlander, D.E. Zhang, R.A. Larson, M.M. Le Beau, M.J. Thirman, T.R. Golub, J.D. Rowley, J. Chen, Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc. Natl. Acad. Sci. U. S. A. 105, 15535–15540 (2008)PubMedCrossRef
21.
H. Seca, G.M. Almeida, J.E. Guimaraes, M.H. Vasconcelos, miR signatures and the role of miRs in acute myeloid leukaemia. Eur. J. Cancer 46, 1520–1527 (2010)PubMedCrossRef
22.
H. Zhao, D. Wang, W. Du, D. Gu, R. Yang, MicroRNA and leukemia: tiny molecule, great function. Crit Rev Oncol Hematol 74, 149–155 (2010)PubMedCrossRef
23.
A. Dixon-McIver, P. East, C.A. Mein, J.B. Cazier, G. Molloy, T. Chaplin, T. Andrew Lister, B.D. Young, S. Debernardi, Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One 3, e2141 (2008)PubMedCrossRef
24.
M. Jongen-Lavrencic, S.M. Sun, M.K. Dijkstra, P.J. Valk, B. Lowenberg, MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 111, 5078–5085 (2008)PubMedCrossRef
25.
C. Nervi, F. Fazi, F. Grignani, Oncoproteins, heterochromatin silencing and microRNAs: a new link for leukemogenesis. Epigenetics 3, 1–4 (2008)PubMedCrossRef
26.
F. Fazi, A. Rosa, A. Fatica, V. Gelmetti, M.L. De Marchis, C. Nervi, I. Bozzoni, A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 123, 819–831 (2005)PubMedCrossRef
27.
F. Fazi, S. Racanicchi, G. Zardo, L.M. Starnes, M. Mancini, L. Travaglini, D. Diverio, E. Ammatuna, G. Cimino, F. Lo-Coco, F. Grignani, C. Nervi, Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell 12, 457–466 (2007)PubMedCrossRef
28.
J.B. Johnnidis, M.H. Harris, R.T. Wheeler, S. Stehling-Sun, M.H. Lam, O. Kirak, T.R. Brummelkamp, M.D. Fleming, F.D. Camargo, Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 451, 1125–1129 (2008)PubMedCrossRef
29.
F. Rosenbauer, S. Koschmieder, U. Steidl, D.G. Tenen, Effect of transcription-factor concentrations on leukemic stem cells. Blood 106, 1519–1524 (2005)PubMedCrossRef
30.
M. Bousquet, C. Quelen, R. Rosati, V. Mansat-De Mas, R. La Starza, C. Bastard, E. Lippert, P. Talmant, M. Lafage-Pochitaloff, D. Leroux, C. Gervais, F. Viguie, J.L. Lai, C. Terre, B. Beverlo, C. Sambani, A. Hagemeijer, P. Marynen, G. Delsol, N. Dastugue, C. Mecucci, P. Brousset, Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med 205, 2499–2506 (2008)PubMedCrossRef
31.
L. Fontana, E. Pelosi, P. Greco, S. Racanicchi, U. Testa, F. Liuzzi, C.M. Croce, E. Brunetti, F. Grignani, C. Peschle, MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nat Cell Biol 9, 775–787 (2007)PubMedCrossRef
32.
S. Mi, Z. Li, P. Chen, C. He, D. Cao, A. Elkahloun, J. Lu, L.A. Pelloso, M. Wunderlich, H. Huang, R.T. Luo, M. Sun, M. He, M.B. Neilly, N.J. Zeleznik-Le, M.J. Thirman, J.C. Mulloy, P.P. Liu, J.D. Rowley, J. Chen, Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc. Natl. Acad. Sci. U. S. A. 107, 3710–3715 (2010)PubMedCrossRef
33.
P. Wong, M. Iwasaki, T.C. Somervaille, F. Ficara, C. Carico, C. Arnold, C.Z. Chen, M.L. Cleary, The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res. 70, 3833–3842 (2010)PubMedCrossRef
34.
R. Garzon, S. Volinia, C.G. Liu, C. Fernandez-Cymering, T. Palumbo, F. Pichiorri, M. Fabbri, K. Coombes, H. Alder, T. Nakamura, N. Flomenberg, G. Marcucci, G.A. Calin, S.M. Kornblau, H. Kantarjian, C.D. Bloomfield, M. Andreeff, C.M. Croce, MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111, 3183–3189 (2008)PubMedCrossRef
35.
R. Popovic, L.E. Riesbeck, C.S. Velu, A. Chaubey, J. Zhang, N.J. Achille, F.E. Erfurth, K. Eaton, J. Lu, H.L. Grimes, J. Chen, J.D. Rowley, N.J. Zeleznik-Le, Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood 113, 3314–3322 (2009)PubMedCrossRef
36.
G. Marcucci, K. Maharry, M.D. Radmacher, K. Mrozek, T. Vukosavljevic, P. Paschka, S.P. Whitman, C. Langer, C.D. Baldus, C.G. Liu, A.S. Ruppert, B.L. Powell, A.J. Carroll, M.A. Caligiuri, J.E. Kolitz, R.A. Larson, C.D. Bloomfield, Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J. Clin. Oncol. 26, 5078–5087 (2008)PubMedCrossRef
37.
M.L. Choong, H.H. Yang, I. McNiece, MicroRNA expression profiling during human cord blood-derived CD34 cell erythropoiesis. Exp. Hematol. 35, 551–564 (2007)PubMedCrossRef
38.
J. Chen, O. Odenike, J.D. Rowley, Leukaemogenesis: more than mutant genes. Nat. Rev. Cancer 10, 23–36 (2010)PubMedCrossRef
39.
G. Marcucci, M.D. Radmacher, K. Maharry, K. Mrozek, A.S. Ruppert, P. Paschka, T. Vukosavljevic, S.P. Whitman, C.D. Baldus, C. Langer, C.G. Liu, A.J. Carroll, B.L. Powell, R. Garzon, C.M. Croce, J.E. Kolitz, M.A. Caligiuri, R.A. Larson, C.D. Bloomfield, MicroRNA expression in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358, 1919–1928 (2008)PubMedCrossRef
40.
C. Thiede, S. Koch, E. Creutzig, C. Steudel, T. Illmer, M. Schaich, G. Ehninger, Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107, 4011–4020 (2006)PubMedCrossRef
41.
R. Garzon, M. Garofalo, M.P. Martelli, R. Briesewitz, L. Wang, C. Fernandez-Cymering, S. Volinia, C.G. Liu, S. Schnittger, T. Haferlach, A. Liso, D. Diverio, M. Mancini, G. Meloni, R. Foa, M.F. Martelli, C. Mecucci, C.M. Croce, B. Falini, Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc. Natl. Acad. Sci. U. S. A. 105, 3945–3950 (2008)PubMedCrossRef
42.
B. Falini, I. Nicoletti, M.F. Martelli, C. Mecucci, Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc + AML): biologic and clinical features. Blood 109, 874–885 (2007)PubMedCrossRef
43.
S. Yekta, I.H. Shih, D.P. Bartel, MicroRNA-directed cleavage of HOXB8 mRNA. Science 304, 594–596 (2004)PubMedCrossRef
44.
R.M. O'Connell, D.S. Rao, A.A. Chaudhuri, M.P. Boldin, K.D. Taganov, J. Nicoll, R.L. Paquette, D. Baltimore, Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 205, 585–594 (2008)PubMedCrossRef
45.
R. Crazzolara, L. Bendall, Emerging treatments in acute lymphoblastic leukemia. Curr Cancer Drug Targets 9, 19–31 (2009)PubMedCrossRef
46.
S. Mi, J. Lu, M. Sun, Z. Li, H. Zhang, M.B. Neilly, Y. Wang, Z. Qian, J. Jin, Y. Zhang, S.K. Bohlander, M.M. Le Beau, R.A. Larson, T.R. Golub, J.D. Rowley, J. Chen, MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc. Natl. Acad. Sci. U. S. A. 104, 19971–19976 (2007)PubMedCrossRef
47.
H. Zhang, X.Q. Luo, P. Zhang, L.B. Huang, Y.S. Zheng, J. Wu, H. Zhou, L.H. Qu, L. Xu, Y.Q. Chen, MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One 4, e7826 (2009)PubMedCrossRef
48.
D. Schotte, J.C. Chau, G. Sylvester, G. Liu, C. Chen, V.H. van der Velden, M.J. Broekhuis, T.C. Peters, R. Pieters, M.L. den Boer, Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia 23, 313–322 (2009)PubMedCrossRef
49.
D.L. Zanette, F. Rivadavia, G.A. Molfetta, F.G. Barbuzano, R. Proto-Siqueira, W.A. Silva-Jr, R.P. Falcao, M.A. Zago, miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz J Med Biol Res 40, 1435–1440 (2007)PubMedCrossRef
50.
A. Ota, H. Tagawa, S. Karnan, S. Tsuzuki, A. Karpas, S. Kira, Y. Yoshida, M. Seto, Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 64, 3087–3095 (2004)PubMedCrossRef
51.
A. Ventura, A.G. Young, M.M. Winslow, L. Lintault, A. Meissner, S.J. Erkeland, J. Newman, R.T. Bronson, D. Crowley, J.R. Stone, R. Jaenisch, P.A. Sharp, T. Jacks, Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132, 875–886 (2008)PubMedCrossRef
52.
L. He, J.M. Thomson, M.T. Hemann, E. Hernando-Monge, D. Mu, S. Goodson, S. Powers, C. Cordon-Cardo, S.W. Lowe, G.J. Hannon, S.M. Hammond, A microRNA polycistron as a potential human oncogene. Nature 435, 828–833 (2005)PubMedCrossRef
53.
M. Inomata, H. Tagawa, Y.M. Guo, Y. Kameoka, N. Takahashi, K. Sawada, MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood 113, 396–402 (2009)PubMedCrossRef
54.
L. O'Connor, A. Strasser, L.A. O'Reilly, G. Hausmann, J.M. Adams, S. Cory, D.C. Huang, Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 17, 384–395 (1998)PubMedCrossRef
55.
C. Dong, M. Ji, C. Ji, microRNAs and their potential target genes in leukemia pathogenesis. Cancer Biol Ther 8, 200–205 (2009)PubMedCrossRef
56.
C. Xiao, L. Srinivasan, D.P. Calado, H.C. Patterson, B. Zhang, J. Wang, J.M. Henderson, J.L. Kutok, K. Rajewsky, Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat. Immunol. 9, 405–414 (2008)PubMedCrossRef
57.
P. Mu, Y.C. Han, D. Betel, E. Yao, M. Squatrito, P. Ogrodowski, E. de Stanchina, A. D'Andrea, C. Sander, A. Ventura, Genetic dissection of the miR-17 92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev. 23, 2806–2811 (2009)PubMedCrossRef
58.
V. Olive, M.J. Bennett, J.C. Walker, C. Ma, I. Jiang, C. Cordon-Cardo, Q.J. Li, S.W. Lowe, G.J. Hannon, L. He, miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 23, 2839–2849 (2009)PubMedCrossRef
59.
60.
M.W. Deininger, J.M. Goldman, J.V. Melo, The molecular biology of chronic myeloid leukemia. Blood 96, 3343–3356 (2000)PubMed
61.
T.G. Lugo, A.M. Pendergast, A.J. Muller, O.N. Witte, Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247, 1079–1082 (1990)PubMedCrossRef
62.
Y.A. Mian, N.J. Zeleznik-Le, MicroRNAs in leukemias: emerging diagnostic tools and therapeutic targets. Curr Drug Targets 11, 801–811 (2010)PubMedCrossRef
63.
K. Woods, J.M. Thomson, S.M. Hammond, Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J. Biol. Chem. 282, 2130–2134 (2007)PubMedCrossRef
64.
K.A. O'Donnell, E.A. Wentzel, K.I. Zeller, C.V. Dang, J.T. Mendell, c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435, 839–843 (2005)PubMedCrossRef
65.
Y. Sylvestre, V. De Guire, E. Querido, U.K. Mukhopadhyay, V. Bourdeau, F. Major, G. Ferbeyre, P. Chartrand, An E2F/miR-20a autoregulatory feedback loop. J. Biol. Chem. 282, 2135–2143 (2007)PubMedCrossRef
66.
L. Venturini, K. Battmer, M. Castoldi, B. Schultheis, A. Hochhaus, M.U. Muckenthaler, A. Ganser, M. Eder, M. Scherr, Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood 109, 4399–4405 (2007)PubMedCrossRef
67.
M.J. Bueno, I. Perez de Castro, M. Gomez de Cedron, J. Santos, G.A. Calin, J.C. Cigudosa, C.M. Croce, J. Fernandez-Piqueras, M. Malumbres, Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 13, 496–506 (2008)PubMedCrossRef
68.
X. Agirre, A. Jimenez-Velasco, E. San Jose-Eneriz, L. Garate, E. Bandres, L. Cordeu, O. Aparicio, B. Saez, G. Navarro, A. Vilas-Zornoza, I. Perez-Roger, J. Garcia-Foncillas, A. Torres, A. Heiniger, M.J. Calasanz, P. Fortes, J. Roman-Gomez, F. Prosper, Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res 6, 1830–1840 (2008)PubMedCrossRef
69.
S. Flamant, W. Ritchie, J. Guilhot, J. Holst, M.L. Bonnet, J.C. Chomel, F. Guilhot, A.G. Turhan, J.E. Rasko, Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica 95, 1325–1333 (2010)PubMedCrossRef
70.
E. San Jose-Eneriz, J. Roman-Gomez, A. Jimenez-Velasco, L. Garate, V. Martin, L. Cordeu, A. Vilas-Zornoza, P. Rodriguez-Otero, M.J. Calasanz, F. Prosper, X. Agirre, MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations. Mol Cancer 8, 69 (2009)PubMedCrossRef
71.
G.A. Calin, M. Ferracin, A. Cimmino, G. Di Leva, M. Shimizu, S.E. Wojcik, M.V. Iorio, R. Visone, N.I. Sever, M. Fabbri, R. Iuliano, T. Palumbo, F. Pichiorri, C. Roldo, R. Garzon, C. Sevignani, L. Rassenti, H. Alder, S. Volinia, C.G. Liu, T.J. Kipps, M. Negrini, C.M. Croce, A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353, 1793–1801 (2005)PubMedCrossRef
72.
G.A. Calin, C.D. Dumitru, M. Shimizu, R. Bichi, S. Zupo, E. Noch, H. Aldler, S. Rattan, M. Keating, K. Rai, L. Rassenti, T. Kipps, M. Negrini, F. Bullrich, C.M. Croce, Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 99, 15524–15529 (2002)PubMedCrossRef
73.
U. Klein, M. Lia, M. Crespo, R. Siegel, Q. Shen, T. Mo, A. Ambesi-Impiombato, A. Califano, A. Migliazza, G. Bhagat, R. Dalla-Favera, The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17, 28–40 (2010)PubMedCrossRef
74.
E.S. Raveche, E. Salerno, B.J. Scaglione, V. Manohar, F. Abbasi, Y.C. Lin, T. Fredrickson, P. Landgraf, S. Ramachandra, K. Huppi, J.R. Toro, V.E. Zenger, R.A. Metcalf, G.E. Marti, Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 109, 5079–5086 (2007)PubMedCrossRef
75.
E. Salerno, B.J. Scaglione, F.D. Coffman, B.D. Brown, A. Baccarini, H. Fernandes, G. Marti, E.S. Raveche, Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity. Mol. Cancer Ther. 8, 2684–2692 (2009)PubMedCrossRef
76.
U. Klein, R. Dalla-Favera, New insights into the pathogenesis of chronic lymphocytic leukemia. Semin Cancer Biol 20, 377–383 (2010)PubMedCrossRef
77.
A. Cimmino, G.A. Calin, M. Fabbri, M.V. Iorio, M. Ferracin, M. Shimizu, S.E. Wojcik, R.I. Aqeilan, S. Zupo, M. Dono, L. Rassenti, H. Alder, S. Volinia, C.G. Liu, T.J. Kipps, M. Negrini, C.M. Croce, miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. U. S. A. 102, 13944–13949 (2005)PubMedCrossRef
78.
G.A. Calin, A. Cimmino, M. Fabbri, M. Ferracin, S.E. Wojcik, M. Shimizu, C. Taccioli, N. Zanesi, R. Garzon, R.I. Aqeilan, H. Alder, S. Volinia, L. Rassenti, X. Liu, C.G. Liu, T.J. Kipps, M. Negrini, C.M. Croce, MiR-15a and miR-16-1 cluster functions in human leukemia. Proc. Natl. Acad. Sci. U. S. A. 105, 5166–5171 (2008)PubMedCrossRef
79.
R.W. Chen, L.T. Bemis, C.M. Amato, H. Myint, H. Tran, D.K. Birks, S.G. Eckhardt, W.A. Robinson, Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood 112, 822–829 (2008)PubMedCrossRef
80.
P.S. Linsley, J. Schelter, J. Burchard, M. Kibukawa, M.M. Martin, S.R. Bartz, J.M. Johnson, J.M. Cummins, C.K. Raymond, H. Dai, N. Chau, M. Cleary, A.L. Jackson, M. Carleton, L. Lim, Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol. Cell. Biol. 27, 2240–2252 (2007)PubMedCrossRef
81.
P.S. Eis, W. Tam, L. Sun, A. Chadburn, Z. Li, M.F. Gomez, E. Lund, J.E. Dahlberg, Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc. Natl. Acad. Sci. U. S. A. 102, 3627–3632 (2005)PubMedCrossRef
82.
V. Fulci, S. Chiaretti, M. Goldoni, G. Azzalin, N. Carucci, S. Tavolaro, L. Castellano, A. Magrelli, F. Citarella, M. Messina, R. Maggio, N. Peragine, S. Santangelo, F.R. Mauro, P. Landgraf, T. Tuschl, D.B. Weir, M. Chien, J.J. Russo, J. Ju, R. Sheridan, C. Sander, M. Zavolan, A. Guarini, R. Foa, G. Macino, Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 109, 4944–4951 (2007)PubMedCrossRef
83.
S. Costinean, N. Zanesi, Y. Pekarsky, E. Tili, S. Volinia, N. Heerema, C.M. Croce, Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 103, 7024–7029 (2006)PubMedCrossRef
84.
C.H. Lawrie, S. Soneji, T. Marafioti, C.D. Cooper, S. Palazzo, J.C. Paterson, H. Cattan, T. Enver, R. Mager, J. Boultwood, J.S. Wainscoat, C.S. Hatton, MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int. J. Cancer 121, 1156–1161 (2007)PubMedCrossRef
85.
T.H. Thai, D.P. Calado, S. Casola, K.M. Ansel, C. Xiao, Y. Xue, A. Murphy, D. Frendewey, D. Valenzuela, J.L. Kutok, M. Schmidt-Supprian, N. Rajewsky, G. Yancopoulos, A. Rao, K. Rajewsky, Regulation of the germinal center response by microRNA-155. Science 316, 604–608 (2007)PubMedCrossRef
86.
B.J. Scaglione, E. Salerno, M. Balan, F. Coffman, P. Landgraf, F. Abbasi, S. Kotenko, G.E. Marti, E.S. Raveche, Murine models of chronic lymphocytic leukaemia: role of microRNA-16 in the New Zealand Black mouse model. Br. J. Haematol. 139, 645–657 (2007)PubMedCrossRef
87.
A. Rodriguez, E. Vigorito, S. Clare, M.V. Warren, P. Couttet, D.R. Soond, S. van Dongen, R.J. Grocock, P.P. Das, E.A. Miska, D. Vetrie, K. Okkenhaug, A.J. Enright, G. Dougan, M. Turner, A. Bradley, Requirement of bic/microRNA-155 for normal immune function. Science 316, 608–611 (2007)PubMedCrossRef
88.
G.T. Bommer, I. Gerin, Y. Feng, A.J. Kaczorowski, R. Kuick, R.E. Love, Y. Zhai, T.J. Giordano, Z.S. Qin, B.B. Moore, O.A. MacDougald, K.R. Cho, E.R. Fearon, p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 17, 1298–1307 (2007)PubMedCrossRef
89.
T.C. Chang, E.A. Wentzel, O.A. Kent, K. Ramachandran, M. Mullendore, K.H. Lee, G. Feldmann, M. Yamakuchi, M. Ferlito, C.J. Lowenstein, D.E. Arking, M.A. Beer, A. Maitra, J.T. Mendell, Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26, 745–752 (2007)PubMedCrossRef
90.
L. He, X. He, L.P. Lim, E. de Stanchina, Z. Xuan, Y. Liang, W. Xue, L. Zender, J. Magnus, D. Ridzon, A.L. Jackson, P.S. Linsley, C. Chen, S.W. Lowe, M.A. Cleary, G.J. Hannon, A microRNA component of the p53 tumour suppressor network. Nature 447, 1130–1134 (2007)PubMedCrossRef
91.
X. He, L. He, G.J. Hannon, The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res. 67, 11099–11101 (2007)PubMedCrossRef
92.
L. He, X. He, S.W. Lowe, G.J. Hannon, microRNAs join the p53 network–another piece in the tumour-suppression puzzle. Nat. Rev. Cancer 7, 819–822 (2007)PubMedCrossRef
93.
J.S. Wei, Y.K. Song, S. Durinck, Q.R. Chen, A.T. Cheuk, P. Tsang, Q. Zhang, C.J. Thiele, A. Slack, J. Shohet, J. Khan, The MYCN oncogene is a direct target of miR-34a. Oncogene 27, 5204–5213 (2008)PubMedCrossRef
94.
C. Welch, Y. Chen, R.L. Stallings, MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26, 5017–5022 (2007)PubMedCrossRef
95.
D. Asslaber, J.D. Pinon, I. Seyfried, P. Desch, M. Stocher, I. Tinhofer, A. Egle, O. Merkel, R. Greil, microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood 115, 4191–4197 (2010)PubMedCrossRef
96.
M. Yamakuchi, M. Ferlito, C.J. Lowenstein, miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. U. S. A. 105, 13421–13426 (2008)PubMedCrossRef
97.
M.K. Dijkstra, K. van Lom, D. Tielemans, F. Elstrodt, A.W. Langerak, M.B. van 't Veer, M. Jongen-Lavrencic, 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia 23, 625–627 (2009)PubMedCrossRef
98.
T. Zenz, J. Mohr, E. Eldering, A.P. Kater, A. Buhler, D. Kienle, D. Winkler, J. Durig, M.H. van Oers, D. Mertens, H. Dohner, S. Stilgenbauer, miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 113, 3801–3808 (2009)PubMedCrossRef
99.
Y. Pekarsky, U. Santanam, A. Cimmino, A. Palamarchuk, A. Efanov, V. Maximov, S. Volinia, H. Alder, C.G. Liu, L. Rassenti, G.A. Calin, J.P. Hagan, T. Kipps, C.M. Croce, Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 66, 11590–11593 (2006)PubMedCrossRef
100.
M.S. Nicoloso, T.J. Kipps, C.M. Croce, G.A. Calin, MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. Br. J. Haematol. 139, 709–716 (2007)PubMedCrossRef
101.
R. Bichi, S.A. Shinton, E.S. Martin, A. Koval, G.A. Calin, R. Cesari, G. Russo, R.R. Hardy, C.M. Croce, Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc. Natl. Acad. Sci. U. S. A. 99, 6955–6960 (2002)PubMedCrossRef
102.
X.J. Yan, E. Albesiano, N. Zanesi, S. Yancopoulos, A. Sawyer, E. Romano, A. Petlickovski, D.G. Efremov, C.M. Croce, N. Chiorazzi, B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 103, 11713–11718 (2006)PubMedCrossRef
103.
S. Marton, M.R. Garcia, C. Robello, H. Persson, F. Trajtenberg, O. Pritsch, C. Rovira, H. Naya, G. Dighiero, A. Cayota, Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia 22, 330–338 (2008)PubMedCrossRef
104.
B. Stamatopoulos, N. Meuleman, B. Haibe-Kains, P. Saussoy, E. Van Den Neste, L. Michaux, P. Heimann, P. Martiat, D. Bron, L. Lagneaux, microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 113, 5237–5245 (2009)PubMedCrossRef
105.
W.C. Cho, MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int. J. Biochem. Cell Biol. 42, 1273–1281 (2010)PubMedCrossRef
106.
S. Rossi, M. Shimizu, E. Barbarotto, M.S. Nicoloso, F. Dimitri, D. Sampath, M. Fabbri, S. Lerner, L.L. Barron, L.Z. Rassenti, L. Jiang, L. Xiao, J. Hu, P. Secchiero, G. Zauli, S. Volinia, M. Negrini, W. Wierda, T.J. Kipps, W. Plunkett, K.R. Coombes, L.V. Abruzzo, M.J. Keating, G.A. Calin, microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 116, 945–952 (2010)PubMedCrossRef
107.
S. Gilad, E. Meiri, Y. Yogev, S. Benjamin, D. Lebanony, N. Yerushalmi, H. Benjamin, M. Kushnir, H. Cholakh, N. Melamed, Z. Bentwich, M. Hod, Y. Goren, A. Chajut, Serum microRNAs are promising novel biomarkers. PLoS One 3, e3148 (2008)PubMedCrossRef
108.
P.S. Mitchell, R.K. Parkin, E.M. Kroh, B.R. Fritz, S.K. Wyman, E.L. Pogosova-Agadjanyan, A. Peterson, J. Noteboom, K.C. O'Briant, A. Allen, D.W. Lin, N. Urban, C.W. Drescher, B.S. Knudsen, D.L. Stirewalt, R. Gentleman, R.L. Vessella, P.S. Nelson, D.B. Martin, M. Tewari, Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 105, 10513–10518 (2008)PubMedCrossRef
109.
M. Tanaka, K. Oikawa, M. Takanashi, M. Kudo, J. Ohyashiki, K. Ohyashiki, M. Kuroda, Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 4, e5532 (2009)PubMedCrossRef
110.
R. Hummel, D.J. Hussey, J. Haier, MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur. J. Cancer 46, 298–311 (2010)PubMedCrossRef
111.
E. Moussay, V. Palissot, L. Vallar, H.A. Poirel, T. Wenner, V. El Khoury, N. Aouali, K. Van Moer, B. Leners, F. Bernardin, A. Muller, P. Cornillet-Lefebvre, A. Delmer, C. Duhem, F. Ries, E. van Dyck, G. Berchem, Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol Cancer 9, 115 (2010)PubMedCrossRef
112.
F. Meng, R. Henson, M. Lang, H. Wehbe, S. Maheshwari, J.T. Mendell, J. Jiang, T.D. Schmittgen, T. Patel, Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130, 2113–2129 (2006)PubMedCrossRef
113.
J. Krutzfeldt, N. Rajewsky, R. Braich, K.G. Rajeev, T. Tuschl, M. Manoharan, M. Stoffel, Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685–689 (2005)PubMedCrossRef
114.
U.A. Orom, S. Kauppinen, A.H. Lund, LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 372, 137–141 (2006)PubMedCrossRef
115.
K.J. Mavrakis, A.L. Wolfe, E. Oricchio, T. Palomero, K. de Keersmaecker, K. McJunkin, J. Zuber, T. James, A.A. Khan, C.S. Leslie, J.S. Parker, P.J. Paddison, W. Tam, A. Ferrando, H.G. Wendel, Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol 12, 372–379 (2010)PubMedCrossRef
116.
D. Schotte, R. Pieters, M.L. Den Boer, MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia 26, 1–12 (2012)PubMedCrossRef
117.
J. Krutzfeldt, S. Kuwajima, R. Braich, K.G. Rajeev, J. Pena, T. Tuschl, M. Manoharan, M. Stoffel, Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res. 35, 2885–2892 (2007)PubMedCrossRef
118.
J. Elmen, M. Lindow, A. Silahtaroglu, M. Bak, M. Christensen, A. Lind-Thomsen, M. Hedtjarn, J.B. Hansen, H.F. Hansen, E.M. Straarup, K. McCullagh, P. Kearney, S. Kauppinen, Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 36, 1153–1162 (2008)PubMedCrossRef
119.
J. Elmen, M. Lindow, S. Schutz, M. Lawrence, A. Petri, S. Obad, M. Lindholm, M. Hedtjarn, H.F. Hansen, U. Berger, S. Gullans, P. Kearney, P. Sarnow, E.M. Straarup, S. Kauppinen, LNA-mediated microRNA silencing in non-human primates. Nature 452, 896–899 (2008)PubMedCrossRef
120.
A.W. Tong, J. Nemunaitis, Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Ther 15, 341–355 (2008)PubMedCrossRef
121.
W. Wu, M. Sun, G.M. Zou, J. Chen, MicroRNA and cancer: Current status and prospective. Int. J. Cancer 120, 953–960 (2007)PubMedCrossRef
122.
Y. Hayashita, H. Osada, Y. Tatematsu, H. Yamada, K. Yanagisawa, S. Tomida, Y. Yatabe, K. Kawahara, Y. Sekido, T. Takahashi, A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 65, 9628–9632 (2005)PubMedCrossRef
123.
S. Volinia, G.A. Calin, C.G. Liu, S. Ambs, A. Cimmino, F. Petrocca, R. Visone, M. Iorio, C. Roldo, M. Ferracin, R.L. Prueitt, N. Yanaihara, G. Lanza, A. Scarpa, A. Vecchione, M. Negrini, C.C. Harris, C.M. Croce, A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U. S. A. 103, 2257–2261 (2006)PubMedCrossRef
124.
G.A. Calin, C.G. Liu, C. Sevignani, M. Ferracin, N. Felli, C.D. Dumitru, M. Shimizu, A. Cimmino, S. Zupo, M. Dono, M.L. Dell'Aquila, H. Alder, L. Rassenti, T.J. Kipps, F. Bullrich, M. Negrini, C.M. Croce, MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl. Acad. Sci. U. S. A. 101, 11755–11760 (2004)PubMedCrossRef
125.
Z. Yu, C. Wang, M. Wang, Z. Li, M.C. Casimiro, M. Liu, K. Wu, J. Whittle, X. Ju, T. Hyslop, P. McCue, R.G. Pestell, A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol 182, 509–517 (2008)PubMedCrossRef
126.
H. Becker, G. Marcucci, K. Maharry, M.D. Radmacher, K. Mrozek, D. Margeson, S.P. Whitman, Y.Z. Wu, S. Schwind, P. Paschka, B.L. Powell, T.H. Carter, J.E. Kolitz, M. Wetzler, A.J. Carroll, M.R. Baer, M.A. Caligiuri, R.A. Larson, C.D. Bloomfield, Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J. Clin. Oncol. 28, 596–604 (2010)PubMedCrossRef
127.
Y. Pekarsky, A. Koval, C. Hallas, R. Bichi, M. Tresini, S. Malstrom, G. Russo, P. Tsichlis, C.M. Croce, Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc. Natl. Acad. Sci. U. S. A. 97, 3028–3033 (2000)PubMedCrossRef
128.
R. Garzon, F. Pichiorri, T. Palumbo, M. Visentini, R. Aqeilan, A. Cimmino, H. Wang, H. Sun, S. Volinia, H. Alder, G.A. Calin, C.G. Liu, M. Andreeff, C.M. Croce, MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 26, 4148–4157 (2007)PubMedCrossRef
129.
D. Sampath, G.A. Calin, V.K. Puduvalli, G. Gopisetty, C. Taccioli, C.G. Liu, B. Ewald, C. Liu, M.J. Keating, W. Plunkett, Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 113, 3744–3753 (2009)PubMedCrossRef
130.
F. Isken, B. Steffen, S. Merk, M. Dugas, B. Markus, N. Tidow, M. Zuhlsdorf, T. Illmer, C. Thiede, W.E. Berdel, H. Serve, C. Muller-Tidow, Identification of acute myeloid leukaemia associated microRNA expression patterns. Br. J. Haematol. 140, 153–161 (2008)PubMedCrossRef
131.
C. Langer, M.D. Radmacher, A.S. Ruppert, S.P. Whitman, P. Paschka, K. Mrozek, C.D. Baldus, T. Vukosavljevic, C.G. Liu, M.E. Ross, B.L. Powell, A. de la Chapelle, J.E. Kolitz, R.A. Larson, G. Marcucci, C.D. Bloomfield, High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 111, 5371–5379 (2008)PubMedCrossRef
132.
C. Xiao, D.P. Calado, G. Galler, T.H. Thai, H.C. Patterson, J. Wang, N. Rajewsky, T.P. Bender, K. Rajewsky, MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 131, 146–159 (2007)PubMedCrossRef
133.
K. Machova Polakova, T. Lopotova, H. Klamova, P. Burda, M. Trneny, T. Stopka, J. Moravcova, Expression patterns of microRNAs associated with CML phases and their disease related targets. Mol Cancer 10, 41 (2011)PubMedCrossRef
134.
R. Garzon, F. Pichiorri, T. Palumbo, R. Iuliano, A. Cimmino, R. Aqeilan, S. Volinia, D. Bhatt, H. Alder, G. Marcucci, G.A. Calin, C.G. Liu, C.D. Bloomfield, M. Andreeff, C.M. Croce, MicroRNA fingerprints during human megakaryocytopoiesis. Proc. Natl. Acad. Sci. U. S. A. 103, 5078–5083 (2006)PubMedCrossRef
135.
H. Bruchova, D. Yoon, A.M. Agarwal, J. Mendell, J.T. Prchal, Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp. Hematol. 35, 1657–1667 (2007)PubMedCrossRef
136.
R.W. Georgantas 3rd, R. Hildreth, S. Morisot, J. Alder, C.G. Liu, S. Heimfeld, G.A. Calin, C.M. Croce, C.I. Civin, CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc. Natl. Acad. Sci. U. S. A. 104, 2750–2755 (2007)PubMedCrossRef
137.
G. Marcucci, K. Mrozek, M.D. Radmacher, R. Garzon, C.D. Bloomfield, The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 117, 1121–1129 (2011)PubMedCrossRef
138.
S. Debernardi, S. Skoulakis, G. Molloy, T. Chaplin, A. Dixon-McIver, B.D. Young, MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis. Leukemia 21, 912–916 (2007)PubMed
139.
U. Thorsteinsdottir, A. Mamo, E. Kroon, L. Jerome, J. Bijl, H.J. Lawrence, K. Humphries, G. Sauvageau, Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood 99, 121–129 (2002)PubMedCrossRef
140.
N. Felli, L. Fontana, E. Pelosi, R. Botta, D. Bonci, F. Facchiano, F. Liuzzi, V. Lulli, O. Morsilli, S. Santoro, M. Valtieri, G.A. Calin, C.G. Liu, A. Sorrentino, C.M. Croce, C. Peschle, MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc. Natl. Acad. Sci. U. S. A. 102, 18081–18086 (2005)PubMedCrossRef
141.
S.M. Tanner, J.L. Austin, G. Leone, L.J. Rush, C. Plass, K. Heinonen, K. Mrozek, H. Sill, S. Knuutila, J.E. Kolitz, K.J. Archer, M.A. Caligiuri, C.D. Bloomfield, A. de La Chapelle, BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc. Natl. Acad. Sci. U. S. A. 98, 13901–13906 (2001)PubMedCrossRef
Metadata
Title
Aberrant microRNA expression and its implications in the pathogenesis of leukemias
Authors
Sadegh Babashah
Majid Sadeghizadeh
Mostafa Rezaei Tavirani
Shirin Farivar
Masoud Soleimani
Publication date
01-10-2012
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 5/2012
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-012-0095-3

Other articles of this Issue 5/2012

Cellular Oncology 5/2012 Go to the issue

Original Paper

Colon cancer cells expressing cell surface GRP78 as a marker for reduced tumorigenicity

Original Paper

Skewed immunological balance between Th17 (CD4+IL17A+) and Treg (CD4+CD25+FOXP3+) cells in human oral squamous cell carcinoma

Original Paper

Identification of a novel short peptide seal specific to CD59 and its effect on HeLa cell growth and apoptosis

Original Paper

Prognostic value of CD44 expression in penile squamous cell carcinoma: a pilot study

Original Paper

Chlorophyllin abrogates canonical Wnt/β-catenin signaling and angiogenesis to inhibit the development of DMBA-induced hamster cheek pouch carcinomas

Original Paper

Molecular diagnosis of minimal residual disease in head and neck cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits